RetinalGenix Technologies Inc. (RTGN)

USD 1.6

(0.0%)

Market Cap (In USD)

28.94 Million

Revenue (In USD)

-

Net Income (In USD)

-2.09 Million

Avg. Volume

-

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.25-3.5
PE
-
EPS
-
Beta Value
-2.7
ISIN
US76133Y1055
CUSIP
CIK
1836295
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Jerry Katzman
Employee Count
-
Website
https://retinalgenix.com
Ipo Date
2022-02-24
Details
RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. Its products include the RetinalGeniX Imaging System, a diabetic non-mydriatic mass retinal imaging and screening device; and RetinalCam, a real-time in-home retinal monitoring, imaging, and physician alert system. The company was incorporated in 2017 and is headquartered in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.